It also opens up for the treatment enhancing Trop2 antibody-drug conjugates (ADCs) effectiveness through demethylating agents and transcription factor modulation for low Trop2 expression cancers, offering a novel therapeutic strategy [39]. Here, TACSTD2 is linked to cancer.